Table 2 Demographic characteristics of the triple vaccine response clusters

From: Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial

 

Cluster 1 n = 10

Cluster 2 n = 26

Cluster 3 n = 15

Cluster 4 n = 32

Cluster 5 n = 28

Cluster 6 n = 13

Cluster 7 n = 20

Cluster 8 n = 18

Cluster 9 n = 28

% Young adults

20

27

26.7

9.4

21.4

23.1

40

16.7

17.9

% Middle-aged

10

38.4

40

37.5

32.1

53.8

25

44.4

42.9

% Older adults

70

34.6

33.3

53.1

46.4

23.1

35

38.9

39.3

Age

Mean (min-max)

60.9 (25–76)

56.6 (25–76)

56.9 (26–76)

64.2 (34–78)

60 (27–75)

58.8 (33–78)

54.7 (30–75)

55.9 (27–76)

58.6 (26–78)

% Males

50

42

46.7

68.8

42.9

30.8

70

44

32

BMI

Mean (min-max)

26.2 (19–34.3)

24.3 (19.2–33)

25.2 (19.9–29.4)

25.5 (18.7–37)

25.5 (19.5–38.8)

25.5 (21.7–33.5)

25.2 (20.1–33)

26.2 (17.4–37)

24.8 (19.6–31.8)

H3N2 pre-vaccination titer median (min-max)

40 (5–160)

31.5*a (5–320)

20 (5–80)

5 (5–80)

5*b (5–40)

20 (5–320)

34 (5–320)

5 (5–80)

34 (5–320)

Frailty index

median (min-max)

0.16 (0.03–0.39)

0.10 (0.0–0.34)

0.11 (0.03–0.27)

0.14 (0.03–0.31)

0.11 (0.0–0.36)

0.13 (0.03–0.27)

0.14 (0.0–0.36)

0.11 (0.0–0.25)

0.13 (0.03–0.24)

EQ-5D-3L

median (min-max)

0.93 (0.72–1)

1 (0.72–1)

1 (0.30–1)

1 (0.30–1)

1 (0.72–1)

0.89 (0.69–1)

0.84 (0.33–1)

1 (0.65–1)

1 (0.68–1)

Number of medications

median (min-max)

3.5 (0–9)

1 (0–8)

2 (0–9)

2 (0–7)

1 (0–10)

1 (0–8)

1.5 (0–11)

1 (0–5)

1 (0–8)

  1. The Kruskall–Wallis test was used to compared all continuous demographic characteristics between the responders groups. The Bonferroni correction was used to correct for multiple testing. The Chi-Squared test (2-sided) was used to compare categorical data between the responder groups. Source data are provided as a Source data file.
  2. *p-value <0.05 but >0.01.
  3. acompared to cluster 5.
  4. bcompared to cluster 7.
Back to article page